Literature DB >> 3567980

Phase II study of N-methylformamide in patients with advanced colorectal cancer.

N S Tchekmedyian, R S Kaplan, M Eisenberger, J Abrams, D Van Echo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3567980

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  3 in total

1.  Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced squamous cancer of the cervix. A Gynecologic Oncology Group study.

Authors:  W P McGuire; J A Blessing; K D Hatch; M L Berman
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study.

Authors:  W P McGuire; J A Blessing; J S Berek; A Munoz
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

3.  Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.

Authors:  E K Rowinsky; L B Grochow; A Hantel; D S Ettinger; B L Vito; R C Donehower
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.